Scholarlink

Purpose <p>To evaluate the efficacy of combined oral curcumin and intravitreal bevacizumab (IVB) in diabetic macular edema (DME).</p> Methods <p>This clinical trial was conducted using a parallel-group, randomized, placebo-controlled design in patients with DME. All participants received IVB at the standard dose at monthly intervals for a total of three doses. Additionally, they were assigned to receive either oral curcumin capsules (40&#xa0;mg) or a matched placebo every 12&#xa0;h for three months, starting at the time of the first IVB injection. Treatment efficacy was assessed by comparing changes in foveal, perifoveal, and parafoveal retinal thickness, central macular volume (CMV), and LogMAR-corrected distance visual acuity (CDVA). Hemoglobin A1c (HbA1c) tests were performed for all patients at baseline and at three months.</p> Results <p>Fifty-two eyes of 52 patients (26 eyes per group) completed the study. The patients’ baseline characteristics were comparable between the groups. Macular thickness and CMV decreased significantly from baseline in both groups, with no statistically significant difference observed between the groups. Similarly, changes in LogMAR CDVA did not differ significantly between the intervention and control groups (MD: 0.08, [95% CI: -0.04 to 0.20]; <i>P</i> = 0.12). Both groups demonstrated a significant reduction in HbA1c levels at three months compared to baseline; however, the difference in HbA1c changes between the groups was statistically significant (<i>P</i> &lt; 0.001), favoring the curcumin group (MD: 0.63%, 95% CI: [0.3-1.0]). No specific systemic or ocular adverse effects were observed in either group during the study.</p> Conclusion <p>Adjunctive treatment with oral curcumin in patients receiving IVB for DME was associated with a significantly greater reduction in HbA1c levels. Despite this metabolic outcome, oral curcumin did not provide additional detectable anatomical or functional benefit over intravitreal bevacizumab alone during the three-month follow-up.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Short-term effects of oral curcumin as adjunct to intravitreal bevacizumab in diabetic macular edema: a randomized clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月3日

查看全文
  • Alireza Dehghani,
  • Abbas Abdali,
  • Mohammad Malekahmadi,
  • Elaheh Foroughi,
  • Mahsa Rafiee Alhossaini,
  • Ali Mohammad Sabzghabaee,
  • Mohsen Pourazizi

摘要

Purpose

To evaluate the efficacy of combined oral curcumin and intravitreal bevacizumab (IVB) in diabetic macular edema (DME).

Methods

This clinical trial was conducted using a parallel-group, randomized, placebo-controlled design in patients with DME. All participants received IVB at the standard dose at monthly intervals for a total of three doses. Additionally, they were assigned to receive either oral curcumin capsules (40 mg) or a matched placebo every 12 h for three months, starting at the time of the first IVB injection. Treatment efficacy was assessed by comparing changes in foveal, perifoveal, and parafoveal retinal thickness, central macular volume (CMV), and LogMAR-corrected distance visual acuity (CDVA). Hemoglobin A1c (HbA1c) tests were performed for all patients at baseline and at three months.

Results

Fifty-two eyes of 52 patients (26 eyes per group) completed the study. The patients’ baseline characteristics were comparable between the groups. Macular thickness and CMV decreased significantly from baseline in both groups, with no statistically significant difference observed between the groups. Similarly, changes in LogMAR CDVA did not differ significantly between the intervention and control groups (MD: 0.08, [95% CI: -0.04 to 0.20]; P = 0.12). Both groups demonstrated a significant reduction in HbA1c levels at three months compared to baseline; however, the difference in HbA1c changes between the groups was statistically significant (P < 0.001), favoring the curcumin group (MD: 0.63%, 95% CI: [0.3-1.0]). No specific systemic or ocular adverse effects were observed in either group during the study.

Conclusion

Adjunctive treatment with oral curcumin in patients receiving IVB for DME was associated with a significantly greater reduction in HbA1c levels. Despite this metabolic outcome, oral curcumin did not provide additional detectable anatomical or functional benefit over intravitreal bevacizumab alone during the three-month follow-up.